Home/Pipeline/RZ-858

RZ-858

Metabolic Disease

PreclinicalActive

Key Facts

Indication

Metabolic Disease

Phase

Preclinical

Status

Active

Company

Rezubio

About Rezubio

Rezubio develops gut-restricted drugs using its Membrane-Anchored Drug Design platform to create safer, more effective treatments for metabolic and inflammatory diseases.

View full company profile

Therapeutic Areas

Metabolic Disease Cardiometabolic Disease Immunology Inflammatory Disease

Other Metabolic Disease Drugs

Drug	Company	Phase	Status
DVI-004	Divamics	Preclinical	Recently disclosed
Undisclosed Peptide Programs	AmideBio	Preclinical	Active
Undisclosed	Junevity	Pre-clinical	Active
Stabilized Peptide Therapeutics (e.g., GLP-1)	Constructive Bio	Pre-clinical	Active
GLP‑1 Peptide Long‑Acting Injectable	Mapi Pharma	Preclinical	Active